Skip to main content

Advertisement

Table 4 Multivariate analysis of prognostic factors

From: Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study

Variate OS PFS DMFS LRRFS
RR(95% CI) P RR(95% CI) P RR(95% CI) P RR(95% CI) P
Group
RV-IMRT vs. CV-IMRT 0.580 (0.257–1.309) 0.19 0.826 (0.420–1.622) 0.578 1.285 (0.538–3.070) 0.573 0.553 (0.203–1.502) 0.245
Gender
 Male vs. Female 0.970 (0.382–2.464) 0.95 1.918 (0.736–4.998) 0.183 2.979 (0.684–12.978) 0.146 1.563 (0.439–5.562) 0.49
Age
  ≥ 45 vs. < 45 2.408 (1.037–5.595) 0.041 1.451 (0.724–2.908) 0.294 1.053 (0.438–2.528) 0.909 1.607 (0.575–4.490) 0.365
T stage
 T3–4 vs. T1–2 0.817 (0.340–1.964) 0.651 0.916 (0.415–2.021) 0.828 1.068 (0.396–2.885) 0.896 1.179 (0.368–3.776) 0.781
N stage
 N2–3 vs. N0–1 2.455 (0.649–9.279) 0.186 2.192 (0.687–6.992) 0.185 2.715 (0.556–13.257) 0.217 1.490 (0.361–6.159) 0.581
Clinical stage
 III-IV vs. I-II 3.280 (0.281–38.226) 0.343 0.926 (0.183–4.683) 0.926 0.730 (0.080–6.639) 0.78 1.165 (0.129–10.480) 0.892
Neoadjuvant/adjuvant chemotherapy
 Yes vs. No 0.600 (0.085–4.238) 0.608 0.695 (0.108–4.464) 0.702 1.764 (0.084–36.960) 0.715 0.404 (0.047–3.457) 0.408
Concurrent chemotherapy
 Yes vs. No 0.987 (0.041–23.701) 0.994 3.338 (0.237–46.915) 0.371 0.796 (0.030–20.935) 0.891
  1. OS overall survival, PFS progression-free survival, DMFS distant metastasis-free survival, LRRFS locoregional recurrence-free survival, CV-IMRT conventional-volume intensity-modulated radiation therapy, RV-IMRT reduced-volume intensity-modulated radiation therapy